A 12 Week Treatment, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Valsartan 160-320 mg With Regard to Effects on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome
Sponsor study identifier
interventional
45
2 countries
2
Study Start
November 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2007
Actual (reported)Study Completion
June 2007
Actual (reported)The purpose of this study is to evaluate potential effects of valsartan on lipid subfractions and other parameters in lipid metabolism in patients with essential hypertension and metabolic syndrome.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2007
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 2005
Date type not reportedThis date has not been verified as actual or estimated.
October 31, 2006
Actual (reported)November 1, 2006
Actual (reported)June 2007
Actual (reported)June 2007
Actual (reported)To evaluate the effect of valsartan 320 mg on small, dense low density lipoprotein (LDL) subfractions in hypertensive patients with metabolic syndrome.
To evaluate the effect of valsartan 320 mg on further lipid subfractions and enzymes related to the lipoprotein metabolism.
To evaluate the effect of valsartan 160-320 mg on blood pressure and pulse rate.
To assess the safety and tolerability of valsartan 160-320mg.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Investigative Centers, Germany
Novartis
Basel, Switzerland
Novartis + 41 61 324 1111 Basel
Novartis Basel+ 41 61 324 1111
45 participants (actual enrollment reported by the registry).
First Submitted
October 31, 2006
First Posted
November 1, 2006
Study Start
November 2005
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Primary Completion
June 2007
Actual (reported)Study Completion
June 2007
Actual (reported)Last Updated
February 24, 2017
Record last verified: 2017-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: